Abstract
Background Distinguishing diseases into distinct subtypes is crucial for study, effective treatment, and the discovery of potential cures. The Open Targets Platform integrates biomedical, genetic, and biochemical datasets with the goal of empowering disease ontologies and gene targets.
However, many disease annotations remain incomplete, necessitating laborious expert medical input. This is particularly painful for rare and orphan diseases, where resources are limited.
Results We present a machine learning approach to identifying diseases with potential subtypes, using the approximately 23,000 diseases documented in Open Targets. We derive and describe novel features for predicting diseases with subtypes, using direct evidence. Machine learning models were applied to analyze feature importance and evaluate predictive performance for discovering known subtypes. Our model achieves a high (89.1%) ROCAUC. We integrated pre-trained deep learning language models and showed their benefits. Furthermore, we identify 515 disease candidates predicted to possess previously unannotated subtypes.
Conclusions Our models can partition diseases into distinct subtypes. This methodology enables a robust, scalable approach for improving knowledge-based annotations and a comprehensive assessment of disease ontology tiers. Our candidates are attractive targets for further study and personalized medicine, potentially aiding in the unveiling of new therapeutic indications for sought-after targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data downloaded from publicly available opentargets data - https://platform.opentargets.org/downloads
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/ddofer/OpenTargets-DiseaseSubtype
List of abbreviations
- PRAUC
- Area under the precision-recall curve.
- CV
- Cross validation.
- EFO
- Experimental Factor Ontology.
- GxE
- Gene x Environment.
- GO
- Gene ontology.
- GWAS
- Genome-wide association studies.
- HP
- Human Phenotype.
- LR
- Logistic regression.
- OBA
- Ontology of Biological Attributes.
- OT
- Open Targets.
- ROCAUC
- Receiver Operating Characteristic Area Under the Curve.
- RF
- Random Forest.
- UKBB
- United Kingdom BioBank.
- SHAP
- Shapley:
- SHapley
- Additive exPlanations.